{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:46Z","timestamp":1786119286512,"version":"build-2736575974"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1097\/bor.0b013e328329ed9f","type":"journal-article","created":{"date-parts":[[2010,2,25]],"date-time":"2010-02-25T01:51:55Z","timestamp":1267062715000},"page":"251-255","source":"Crossref","is-referenced-by-count":1,"title":["Anticytokine therapy in non-rheumatoid arthritis indications in 2009"],"prefix":"10.1097","volume":"21","author":[{"given":"Alexandra","family":"Villa-Forte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210128","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"key":"R3-10-20210128","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R5-10-20210128","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/art.23687","article-title":"Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies","volume":"58","author":"Hoffman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R6-10-20210128","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R7-10-20210128","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/ard.2007.078139","article-title":"Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis","volume":"67","author":"Davis","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R8-10-20210128","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"Van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R9-10-20210128","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis. Results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"Van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R10-10-20210128","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/art.20977","article-title":"Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor \u03b1 receptor fusion protein etanercept","volume":"52","author":"Baraliakos","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R11-10-20210128","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1002\/art.23044","article-title":"Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study","volume":"56","author":"Lambert","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R12-10-20210128","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/art.21790","article-title":"Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study","volume":"54","author":"Braun","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R13-10-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11280","article-title":"Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation","volume":"11","author":"McLeod","year":"2007","journal-title":"Health Technol Assess"},{"key":"R14-10-20210128","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/ard.2005.040758","article-title":"First update of the international ASAS consensus statement for the use of anti TNF agents in patients with ankylosing spondylitis","volume":"65","author":"Braun","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R15-10-20210128","first-page":"1953","article-title":"Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography: a prospective, longitudinal study","volume":"26","author":"Oostveen","year":"1999","journal-title":"J Rheumatol"},{"key":"R16-10-20210128","first-page":"531","article-title":"Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the antitumor necrosis factor-\u03b1 fusion receptor protein etanercept","volume":"31","author":"Brandt","year":"2004","journal-title":"J Rheumatol"},{"key":"R17-10-20210128","first-page":"118","article-title":"Successful short term treatment of severe undifferentiated spondyloarthropathy with the antitumor necrosis factor-\u03b1 monoclonal antibody infliximab","volume":"29","author":"Brandt","year":"2002","journal-title":"J Rheumatol"},{"key":"R18-10-20210128","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/art.23606","article-title":"Efficacy of adalimumab in the treatment of axial spondyloarthritis without radiographically defined sacroiliitis. Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two","volume":"58","author":"Haibel","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R19-10-20210128","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/ard.2003.016386","article-title":"Prediction of a major clinical response (BASDAI 50) to tumor necrosis factor \u03b1 blockers in ankylosing spondylitis","volume":"63","author":"Rudwaleit","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R20-10-20210128","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1136\/ard.2006.066415","article-title":"Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes","volume":"66","author":"Baraliakos","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R21-10-20210128","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11926-008-0058-x","article-title":"Spondyloarthritis at the crossroads of imaging, pathology, and structural damage in the era of biologics","volume":"10","author":"Appel","year":"2008","journal-title":"Curr Rheumatol Rep"},{"key":"R22-10-20210128","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/art.24132","article-title":"Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis","volume":"60","author":"Maksymowych","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R23-10-20210128","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23471","article-title":"Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept","volume":"58","author":"van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R24-10-20210128","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1002\/art.23901","article-title":"Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis","volume":"58","author":"van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R25-10-20210128","first-page":"809","article-title":"Longitudinal study of clinical and radiological progression in psoriatic arthritis","volume":"17","author":"Gladman","year":"1999","journal-title":"J Rheumatol"},{"key":"R26-10-20210128","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R27-10-20210128","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R28-10-20210128","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Results of the double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R29-10-20210128","first-page":"869","article-title":"Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"35","author":"Antoni","year":"2008","journal-title":"J Rheumatol"},{"key":"R30-10-20210128","first-page":"883","article-title":"Risks and benefits of tumor necrosis factor-\u03b1 inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials","volume":"35","author":"Saad","year":"2008","journal-title":"J Rheumatol"},{"key":"R31-10-20210128","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/ard.2005.045658","article-title":"The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year","volume":"65","author":"Kavanaugh","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R32-10-20210128","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/art.22379","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial","volume":"56","author":"Gladman","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R33-10-20210128","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1136\/ard.2006.058339","article-title":"Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial","volume":"66","author":"Kavanaugh","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R34-10-20210128","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/BOR.0b013e3283060778","article-title":"Update on biologics in juvenile idiopathic arthritis","volume":"20","author":"Ilowite","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"R35-10-20210128","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/ard.2005.047225","article-title":"Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis","volume":"65","author":"Tynjala","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R36-10-20210128","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/rheumatology\/keh592","article-title":"Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis","volume":"44","author":"Siminini","year":"2005","journal-title":"Rheumatology"},{"key":"R37-10-20210128","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"R38-10-20210128","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"key":"R39-10-20210128","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/art.23427","article-title":"Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis","volume":"58","author":"Lovell","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R40-10-20210128","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R41-10-20210128","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/ard.2006.058248","article-title":"Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis","volume":"66","author":"Tynjala","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R42-10-20210128","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/bjo.2006.103721","article-title":"Adalimumab in the therapy of uveitis in childhood","volume":"91","author":"Biester","year":"2007","journal-title":"Br J Ophthalmol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0b013e328329ed9f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:11:05Z","timestamp":1786039865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002281-200905000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e328329ed9f","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}